<DOC>
	<DOCNO>NCT00744315</DOCNO>
	<brief_summary>Human Vascular Endothelial Grown Factor 165 ( hVEGF165 ) administration promise therapy induces new vessel , arteriole capillary region whose revascularization surgery possible direct percutaneous angioplasty . This study aim evaluate clinical effect safety gene therapy hVEGF165 patient advance coronary artery disease .</brief_summary>
	<brief_title>Induced Angiogenesis Genic Therapy Advanced Ischemic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Diagnosis coronary artery disease symptomatic , despite optimal pharmacologic therapy Left ventricular dysfunction leave ventricular ejection fraction 60 % 25 % echocardiogram Nonconventional revascularization , see cineangiocardiography , attest interventional cardiologist cardiac surgeon Age 75 year Absence neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>myocardial revascularization</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>genetics , medical</keyword>
	<keyword>Angiogenesis Inducing Agents</keyword>
</DOC>